Untreated vision loss, high LDL cholesterol risk factors for dementia
Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia,.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Researchers have added two additional risk factors — untreated vision loss and high LDL cholesterol — to 12 other steps to identify dementia,.
Novo Nordisk’s end-stage trial for hypertension drug has failed to meet its primary goal and the Danish multinational has recognised an impairment loss.
HQ Team March 27, 2024: The US regulator, the Food and Drug Administration, has approved Winrevair therapy of Merck & Co., Inc., to.
HQ Team February 13, 2024: Adding to the long line of evidence that reducing salt intake affects blood pressure is the latest study.
Otsuka Medical Devices Co., announced its treatment for hypertension has got approval from the US Food and Drug Administration.
HQ Team October 16, 2023: Danish pharmaceutical company, Novo Nordisk, announced it was buying a hypertension drug, still in trials, from Singapore-based KBP.
HQ Team September 19, 2023: More than 1,000 people globally die of strokes and heart attacks every hour, mostly due to high blood.
HQ Team September 7, 2023: Johnson & Johnson has decided to halt an experimental trial, in its final stages, on a drug to.
HQ Team August 18, 2023: Japan’s radiologists using chest radiographs developed an AI model to accurately predict a human’s chronological age and detect.
HQ Team July 25, 2023: Switzerland’s healthcare company, Roche, signed a pact with US-based Alnylam to jointly develop and commercialize a therapy to.